Back

VERVE-101: a promising CRISPR-based gene editing therapy that reduces LDL-C and PCSK9 levels in HeFH patients

European Heart Journal - Cardiovascular Pharmacotherapy

23 December 2023
Organised by: Logo
Read full article
ESC Journals

Contributors

Takahiro Horie
Takahiro Horie

Author

Kyoto University Hospital Kyoto , Japan

Koh Ono
Koh Ono

Author

You may be interested in
thumbnail
Congress Presentation
An investigational in vivo base editing medicine targeting ANGPTL3, VERVE-201, achieves potent and LDLR-independent liver editing in mouse models
27 August 2023
thumbnail
Congress Presentation
Effectiveness of PCSK9 inhibitors in homozygous familial hypercholesterolemia: insights from a Saudi Arabia genetic population
3 April 2025
thumbnail
Webinar
How to treat patients with borderline dyslipidemia
8 February 2023
thumbnail
Congress Presentation
Efficacy and safety of inclisiran in patients with established cerebrovascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised clinical trials
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources